BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 22689177)

  • 1. Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor.
    Hiltermann TJN; Pore MM; van den Berg A; Timens W; Boezen HM; Liesker JJW; Schouwink JH; Wijnands WJA; Kerner GSMA; Kruyt FAE; Tissing H; Tibbe AGJ; Terstappen LWMM; Groen HJM
    Ann Oncol; 2012 Nov; 23(11):2937-2942. PubMed ID: 22689177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of circulating tumor cells' reduction in patients with extensive small-cell lung cancer.
    Normanno N; Rossi A; Morabito A; Signoriello S; Bevilacqua S; Di Maio M; Costanzo R; De Luca A; Montanino A; Gridelli C; Rocco G; Perrone F; Gallo C
    Lung Cancer; 2014 Aug; 85(2):314-9. PubMed ID: 24882383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive and prognostic value of folate receptor-positive circulating tumor cells in small cell lung cancer patients treated with first-line chemotherapy.
    Shen J; Zhao J; Jiang T; Li X; Zhao C; Su C; Zhou C
    Oncotarget; 2017 Jul; 8(30):49044-49052. PubMed ID: 28467771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
    Zhu HH; Liu YT; Feng Y; Zhang LN; Zhang TM; Dong GL; Xing PY; Wang HY; Shi YK; Hu XS
    Thorac Cancer; 2021 Oct; 12(20):2749-2757. PubMed ID: 34423906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
    Aggarwal C; Wang X; Ranganathan A; Torigian D; Troxel A; Evans T; Cohen RB; Vaidya B; Rao C; Connelly M; Vachani A; Langer C; Albelda S
    Lung Cancer; 2017 Oct; 112():118-125. PubMed ID: 29191584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Clinical Utility of Circulating Tumor Cells at Different Time Points in Predicting Prognosis of Patients With Small Cell Lung Cancer: A Meta-Analysis.
    Jiang AM; Zheng HR; Liu N; Zhao R; Ma YY; Bai SH; Tian T; Liang X; Ruan ZP; Fu X; Yao Y
    Cancer Control; 2021; 28():10732748211050581. PubMed ID: 34654345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic impact of circulating tumor cells in patients with small cell lung cancer.
    Naito T; Tanaka F; Ono A; Yoneda K; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Kenmotsu H; Shukuya T; Kaira K; Koh Y; Endo M; Hasegawa S; Yamamoto N
    J Thorac Oncol; 2012 Mar; 7(3):512-9. PubMed ID: 22258473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor cell counts/change for outcome prediction in patients with extensive-stage small-cell lung cancer.
    Cheng Y; Liu XQ; Fan Y; Liu YP; Liu Y; Liu Y; Ma LX; Liu XH; Li H; Bao HZ; Liu JJ; Zhang S; Wu CJ
    Future Oncol; 2016 Mar; 12(6):789-99. PubMed ID: 26838372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic changes of phenotypically different circulating tumor cells sub-populations in patients with recurrent/refractory small cell lung cancer treated with pazopanib.
    Messaritakis I; Politaki E; Koinis F; Stoltidis D; Apostolaki S; Plataki M; Dermitzaki EK; Georgoulias V; Kotsakis A
    Sci Rep; 2018 Feb; 8(1):2238. PubMed ID: 29396560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of circulating tumour cells in limited-stage small-cell lung cancer: analysis of the concurrent once-daily versus twice-daily radiotherapy (CONVERT) randomised controlled trial.
    Tay RY; Fernández-Gutiérrez F; Foy V; Burns K; Pierce J; Morris K; Priest L; Tugwood J; Ashcroft L; Lindsay CR; Faivre-Finn C; Dive C; Blackhall F
    Ann Oncol; 2019 Jul; 30(7):1114-1120. PubMed ID: 31020334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of circulating tumor cells in evaluation of prognosis and treatment response in advanced non-small-cell lung cancer.
    Zhou J; Dong F; Cui F; Xu R; Tang X
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):825-833. PubMed ID: 28289866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic and predictive value of circulating tumor cells and CXCR4 expression as biomarkers for a CXCR4 peptide antagonist in combination with carboplatin-etoposide in small cell lung cancer: exploratory analysis of a phase II study.
    Salgia R; Weaver RW; McCleod M; Stille JR; Yan SB; Roberson S; Polzer J; Flynt A; Raddad E; Peek VL; Wijayawardana SR; Um SL; Gross S; Connelly MC; Morano C; Repollet M; Sanders R; Baeten K; D'Haese D; Spigel DR
    Invest New Drugs; 2017 Jun; 35(3):334-344. PubMed ID: 28299514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TTF-1- and/or CD56-positive Circulating Tumor Cells in patients with small cell lung cancer (SCLC).
    Messaritakis I; Stoltidis D; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Politaki E; Apostolaki S; Souglakos J; Georgoulias V
    Sci Rep; 2017 Mar; 7():45351. PubMed ID: 28349943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy.
    Hou JM; Greystoke A; Lancashire L; Cummings J; Ward T; Board R; Amir E; Hughes S; Krebs M; Hughes A; Ranson M; Lorigan P; Dive C; Blackhall FH
    Am J Pathol; 2009 Aug; 175(2):808-16. PubMed ID: 19628770
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients.
    Shi WL; Li J; Du YJ; Zhu WF; Wu Y; Hu YM; Chen YC
    Med Oncol; 2013 Dec; 30(4):755. PubMed ID: 24178178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Size-based isolation of circulating tumor cells in lung cancer patients using a microcavity array system.
    Hosokawa M; Kenmotsu H; Koh Y; Yoshino T; Yoshikawa T; Naito T; Takahashi T; Murakami H; Nakamura Y; Tsuya A; Shukuya T; Ono A; Akamatsu H; Watanabe R; Ono S; Mori K; Kanbara H; Yamaguchi K; Tanaka T; Matsunaga T; Yamamoto N
    PLoS One; 2013; 8(6):e67466. PubMed ID: 23840710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib or cixutumumab in combination with standard chemotherapy for patients with extensive-stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E1508).
    Belani CP; Dahlberg SE; Rudin CM; Fleisher M; Chen HX; Takebe N; Velasco MR; Tester WJ; Sturtz K; Hann CL; Shanks JC; Monga M; Ramalingam SS; Schiller JH
    Cancer; 2016 Aug; 122(15):2371-8. PubMed ID: 27163943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic characterization of circulating tumor cells in the peripheral blood of patients with small cell lung cancer.
    Messaritakis I; Politaki E; Kotsakis A; Dermitzaki EK; Koinis F; Lagoudaki E; Koutsopoulos A; Kallergi G; Souglakos J; Georgoulias V
    PLoS One; 2017; 12(7):e0181211. PubMed ID: 28719656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib.
    Messaritakis I; Politaki E; Plataki M; Karavassilis V; Kentepozidis N; Koinis F; Samantas E; Georgoulias V; Kotsakis A
    Lung Cancer; 2017 Feb; 104():16-23. PubMed ID: 28212995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of circulating tumor cells in patients with small-cell lung cancer.
    Wang YL; Liu CH; Li J; Ma XP; Gong P
    Tumori; 2017 May; 103(3):242-248. PubMed ID: 28218384
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.